Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 06:36:56 ON 01 MAY 2008

=>
=> fil reg
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                             ENTRY   SESSION
FULL ESTIMATED COST   0.21   0.21

FILE 'REGISTRY' ENTERED AT 06:37:06 ON 01 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 APR 2008 HIGHEST RN 1018615-45-6
DICTIONARY FILE UPDATES: 30 APR 2008 HIGHEST RN 1018615-45-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10530840.str



chain nodes :
10 11 12 13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-12 9-10 10-11 12-13 13-14 13-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 6-9 7-8 7-12 8-9 9-10 10-11 12-13 13-14 13-15
normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS

L1   STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 06:37:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   40 TO ITERATE

100.0% PROCESSED   40 ITERATIONS   13 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 421 TO   1179
PROJECTED ANSWERS: 44 TO   476

L2   13 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 06:37:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   700 TO ITERATE

100.0% PROCESSED   700 ITERATIONS   195 ANSWERS
SEARCH TIME: 00.00.01

L3   195 SEA SSS FUL L1

```
=> s l3 and caplus/lc
      56590141 CAPLUS/LC
L4          182 L3 AND CAPLUS/LC

=> s l3 not l4
L5           13 L3 NOT L4

=> d l5 1-13
```

L5 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 956088-08-7 REGISTRY
ED Entered STN: 28 Nov 2007
CN 1H-Indazole-3-carboxylic acid, 1-[2-(1,3-benzodioxol-5-ylamino)-2-oxoethyl]-, methyl ester (CA INDEX NAME)
MF C18 H15 N3 O5
SR Chemical Library
Supplier: TimTec, Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 2 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 945145-44-8 REGISTRY
ED Entered STN: 21 Aug 2007
CN 1H-Indazole-3-carboxylic acid, 1-[2-oxo-2-[(2-oxo-2-phenylethyl)amino]ethyl]-, methyl ester (CA INDEX NAME)
MF C19 H17 N3 O4
SR Chemical Library
Supplier: Scientific Exchange, Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 3 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 933028-88-7 REGISTRY
ED Entered STN: 29 Apr 2007
CN 1H-Indazole-1-acetamide, N-[(4-chlorophenyl)methyl]-3-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)
MF C21 H21 Cl N4 O2
SR Chemical Library
Supplier: Aurora Fine Chemicals
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 4 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 932992-46-6 REGISTRY
ED Entered STN: 27 Apr 2007
CN 1H-Indazole-1-acetamide, N-(4-chlorophenyl)-3-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)
MF C20 H19 Cl N4 O2
SR Chemical Library
Supplier: Aurora Fine Chemicals
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 5 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 869783-64-2 REGISTRY
ED Entered STN: 13 Dec 2005
CN 1H-Indazole-1-carboxamide,
N-cyclopentyl-5-[[(cyclopentylamino)carbonyl]am
ino]-3-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)- (CA INDEX NAME)
MF C27 H37 N7 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 6 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 869783-60-8 REGISTRY
ED Entered STN: 13 Dec 2005
CN 1H-Indazole-1-carboxamide, 3-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-N-

[(4-fluorophenyl)methyl]-5-[[[[(4-fluorophenyl)methyl]amino]carbonyl]amino
]- (CA INDEX NAME)
MF C31 H31 F2 N7 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 7 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 869783-56-2 REGISTRY
ED Entered STN: 13 Dec 2005
CN 1H-Indazole-1-carboxamide, 3-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-N-

[(3-methoxyphenyl)methyl]-5-[[[[(3-methoxyphenyl)methyl]amino]carbonyl]ami
no]- (CA INDEX NAME)
MF C33 H37 N7 O5
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 8 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 865886-25-5 REGISTRY
ED Entered STN: 24 Oct 2005
CN Carbamic acid,
[3-[[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]-1-[[(1-
methylethyl)amino]carbonyl]-1H-indazol-5-yl]-, 1-methylethyl ester (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C23 H32 N6 O4
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 9 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 865885-93-4 REGISTRY
ED Entered STN: 24 Oct 2005
CN 1H-Indazole-1,3-dicarboxamide, N3-(3S)-1-azabicyclo[2.2.2]oct-3-yl-N1-propyl-5-[[(propylamino)carbonyl]amino]- (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H33 N7 O3
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 10 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 865885-91-2 REGISTRY
ED Entered STN: 24 Oct 2005
CN 1H-Indazole-1,3-dicarboxamide, N3-(3R)-1-azabicyclo[2.2.2]oct-3-yl-N1-cyclopentyl-5-[[(cyclopentylamino)carbonyl]amino]- (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H37 N7 O3
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 11 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 858661-44-6 REGISTRY
ED Entered STN: 07 Aug 2005
CN 1H-Indazole-1-carboxamide, N-cyclopentyl-5-[[(cyclopentylamino)carbonyl]amino]-3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]- (CA INDEX NAME)
MF C27 H37 N7 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 12 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 858661-40-2 REGISTRY
ED Entered STN: 07 Aug 2005
CN 1H-Indazole-1-carboxamide, N-[(4-fluorophenyl)methyl]-5-[[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]-3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]- (CA INDEX NAME)
MF C31 H31 F2 N7 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 13 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 858661-36-6 REGISTRY
ED Entered STN: 07 Aug 2005
CN 1H-Indazole-1-carboxamide, 3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]-N-propyl-5-[[(propylamino)carbonyl]amino]- (CA INDEX NAME)
MF C23 H33 N7 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     209.51     209.72

FILE 'CAPLUS' ENTERED AT 06:37:52 ON 01 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 1 May 2008  VOL 148 ISS 18
FILE LAST UPDATED: 30 Apr 2008  (20080430/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 06:36:56 ON 01 MAY 2008)

     FILE 'REGISTRY' ENTERED AT 06:37:06 ON 01 MAY 2008
L1             STRUCTURE UPLOADED
L2          13 S L1
L3         195 S L1 FULL
L4         182 S L3 AND CAPLUS/LC
L5          13 S L3 NOT L4

     FILE 'CAPLUS' ENTERED AT 06:37:52 ON 01 MAY 2008

=> s l4
L6          15 L4

=> d ibib abs hitstr 1-15
```

L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:319632 CAPLUS
DOCUMENT NUMBER: 148:331704
TITLE: Oxoquinazoline compounds as ophthalmic compositions for treating ocular hypertension and their preparation
INVENTOR(S): Doherty, James B.; Shu, Min; Shen, Dong-Ming
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 48pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008030390	A2	20080313	WO 2007-US19123	20070831

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-842224P P 20060905

GI



I



II

L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB This invention relates to potent potassium channel blocker compds. of formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compds. to provide a neuroprotective effect to the eye of mammalian species, particularly humans. Compds. of formula I wherein V and V' are independently (un)substituted (mono/di/triaza)indazolyl, (un)substituted (mono/bi/triaza)quinazolinyl, (un)substituted (mono/bi/tri)indolyl, (un)substituted (mono/bi/triaza)benzofuranyl. (un)substituted naphthalenyl, etc.; Y1 and Y2 are independently O and H2; Q and Q' are independently O, NH and derivs., and a bond; W is (un)substituted C1-10 alkyl diradical optionally interrupted by C6-10 aryl, C5-10 heteroaryl,et c.; X and X' are independently (CHR7)0-2; R7 is H, C1-6 alkyl, (CH2)0-3-CO2H and derivs., and (CH2)0-3-NH2 and derivs.; and their pharmaceutically acceptable salts, hydrolyzable esters, enantiomers, diastereoisomers and mixture thereof, are claimed. Example compound II was prepared by coupling of (3-tert-butyl-7-methoxy-2-oxoquinazolin-1(2H)-yl)acetic acid with N-butyl-3-hydroxy-2,2-dimethylpropylamine. All the invention compds. were evaluated for their potassium channel inhibitory activity (some data given).

IT 1011485-64-5P 1011485-65-6P 1011485-66-7P
1011485-67-8P 1011485-68-9P 1011485-69-0P
1011485-70-3P 1011485-71-4P 1011485-72-5P
1011485-73-6P 1011485-74-7P 1011485-75-8P
1011485-76-9P 1011485-77-0P 1011485-90-7P
1011485-91-8P 1011485-92-9P 1011485-93-0P
1011485-94-1P 1011485-95-2P 1011485-96-3P
1011485-97-4P 1011485-98-5P 1011485-99-6P
1011486-00-2P 1011486-01-3P 1011486-02-4P
1011486-03-5P 1011486-04-6P 1011486-05-7P
1011486-06-8P 1011486-07-9P 1011486-08-0P
1011486-09-1P 1011486-10-4P 1011486-11-5P
1011486-12-6P 1011486-13-7P 1011486-14-8P
1011486-15-9P 1011486-16-0P 1011486-17-1P
1011486-18-2P 1011486-29-5P 1011486-30-8P
1011486-31-9P 1011486-32-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of oxoquinazoline compds. as potassium channel blockers and their ophthalmic compns. for treating ocular hypertension)

RN 1011485-64-5 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-(2-methyl-1-oxopropyl)-, 2-[[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl](3-methylbutyl)amino]ethyl ester (CA INDEX NAME)

L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1011485-65-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-66-7 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-(2-methyl-1-oxopropyl)-, 4-[butyl[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl]amino]butyl ester (CA INDEX NAME)



L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 1011485-67-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-68-9 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-(2-methyl-1-oxopropyl)-, 4-[[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl](3-methylbutyl)amino]butyl ester (CA INDEX NAME)



RN 1011485-69-0 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-(2-methyl-1-oxopropyl)-, 3-[[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl](3-methylbutyl)amino]-2,2-dimethylpropyl ester (CA INDEX NAME)



RN 1011485-70-3 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-(2-methyl-1-oxopropyl)-, 3-[butyl[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl]amino]-2,2-dimethylpropyl ester (CA INDEX NAME)



RN 1011485-71-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-72-5 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-(2-methyl-1-oxopropyl)-, 2-[[2-(dimethylamino)ethyl][2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl]amino]ethyl ester (CA INDEX NAME)



RN 1011485-73-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-74-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-75-8 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-(2-methyl-1-oxopropyl)-, 4-[cyclohexyl[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl]amino]butyl ester (CA INDEX NAME)



RN 1011485-76-9 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-(2-methyl-1-oxopropyl)-, 2-[ethyl[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl]amino]ethyl ester (CA INDEX NAME)



RN 1011485-77-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-90-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-91-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-92-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-93-0 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-N-[2-[[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl]amino]ethyl]-N-methyl-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)





RN 1011485-97-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-98-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

RN 1011485-94-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-[2-[ethyl[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl]amino]ethyl]-6-methoxy-N-methyl-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 1011485-95-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-96-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-99-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-00-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-01-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-02-4 CAPLUS
CN 1H-Indazole-1-acetamide,
N-ethyl-6-methoxy-N-[4-[[2-[6-methoxy-3-(2-methyl-

1-oxopropyl)-1H-indazol-1-yl]acetyl]amino]butyl]-3-(2-methyl-1-oxopropyl)-
(CA INDEX NAME)



RN 1011486-03-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-04-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-05-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-06-8 CAPLUS
CN 1H-Indazole-1-acetamide,
N-ethyl-6-methoxy-N-[6-[[2-[6-methoxy-3-(2-methyl-

1-oxopropyl)-1H-indazol-1-yl]acetyl]amino]hexyl]-3-(2-methyl-1-oxopropyl)-
(CA INDEX NAME)



RN 1011486-07-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-08-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-09-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-ethyl-6-methoxy-N-[2-[2-[[2-[6-methoxy-3-(2-

methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl]amino]ethoxy]ethyl]-3-(2-methyl-
1-oxopropyl)- (CA INDEX NAME)



RN 1011486-10-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 1-B

RN 1011486-11-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-12-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-15-9 CAPLUS
CN 1H-Indazole-1-acetic acid, 3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-, 3-[butyl[2-[3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-1H-indazol-1-yl]acetyl]amino]-2,2-dimethylpropyl ester (CA INDEX NAME)



RN 1011486-16-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1011486-13-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-14-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

RN 1011486-17-1 CAPLUS
CN 1H-Indazole-1-acetic acid, 3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-, 2-[[2-[3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-1H-indazol-1-yl]acetyl]ethylamino]ethyl ester (CA INDEX NAME)



RN 1011486-18-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-29-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-30-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-31-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-32-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



ACCESSION NUMBER: 2007:384736 CAPLUS
DOCUMENT NUMBER: 146:402148
TITLE: Preparation of azabicyclic derivatives of indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines for therapeutic use as α7-nACh receptor activators
INVENTOR(S): Schumacher, Richard; Danca, Mihaela Diana; Ma, Jianguo; Herbert, Brian; Nguyen, Truc Minh; Xie, Wenge; Tehim, Ashok
PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 283pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007038367	A1	20070405	WO 2006-US37142	20060922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20070078147	A1	20070405	US 2006-525213	20060922
PRIORITY APPLN. INFO.:			US 2005-719552P P	20050923
			US 2006-791881P P	20060414

OTHER SOURCE(S): MARPAT 146:402148
GI



I II

AB N-azabicyclo[2.2.2]octyl-heterocyclic amide derivs., such as I [R = heterocyclyl, such as those cited in the title], were prepared as α7 nicotinic acetylcholine receptor (α7-nAChR) ligands which activate or enhance defective or malfunctioning nAChR activity, especially of the brain, and are useful in the treatment of psychotic disease, neurodegenerative

disease and conditions of memory and/or cognition impairment. These diseases and conditions may include schizophrenia, anxiety, mania, depression, manic depression, Tourette's syndrome, Parkinson's disease, Huntington's disease, Alzheimer's disease, Lewy body dementia, amyotrophic lateral sclerosis, memory impairment, memory loss, cognition deficit, attention deficit, attention deficit hyperactivity disorder (ADHD) and mild cognitive impairment due to aging, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia, HIV and/or cardiovascular disease. Theses diseases may further include alc. and nicotine addiction, pain, jet lag, obesity, diabetes, vascular dementia (VaD), age-assocd. cognitive decline (AACD), amnesia assocd. with open-heart-surgery, cardiac arrest, general anesthesia, memory deficits from exposure to anesthetic agents, sleep deprivation induced cognitive impairment, chronic fatigue syndrome, narcolepsy, AIDS-related dementia, epilepsy-related cognitive impairment, Down's syndrome, alcoholism related dementia, drug/substance induced memory impairments and dementia puglistica (boxer syndrome). Thus, amide II was prepd. via an amidation reaction of (3S)-3-aminoquinuclidine hydrochloride with Et 6-bromobenzisoxazole-3-carboxylate in EtOH using N,N-diisopropylethylamine. The prepd. amides were assayed for α7-nAChR binding affinity.

IT 932703-78-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azabicyclic derivs. of indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines for therapeutic use as α7-nACh receptor activators)

RN 932703-78-1 CAPLUS
CN 1H-Indazole-1,3-dicarboxamide, N1,N3-bis[(3S)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:513768 CAPLUS
DOCUMENT NUMBER: 145:27984
TITLE: 3-(3,4,5-Trimethoxybenzoyl)indazoles and related compounds as tubulin binding anticancer agents and prodrugs thereof; Their preparation, pharmaceutical composition and use for treatment of cancers
INVENTOR(S): Matteucci, Mark; Duan, Jian-Xin; Cai, Xiaohong
PATENT ASSIGNEE(S): Threshold Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006057946	A2	20060601	WO 2005-US42095	20051117
WO 2006057946	A3	20070705		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2005309761	A1	20060601	AU 2005-309761	20051117
CA 2587210	A1	20060601	CA 2005-2587210	20051117
EP 1819338	A2	20070822	EP 2005-826480	20051117
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101094838	A	20071226	CN 2005-80045633	20051117
MX 200706102	A	20070711	MX 2007-6102	20070521
IN 2007DN04648	A	20070817	IN 2007-DN4648	20070618
NO 2007003211	A	20070821	NO 2007-3211	20070622
KR 2007086595	A	20070827	KR 2007-714342	20070622

PRIORITY APPLN. INFO.:			
	US 2004-630422P	P	20041122
	US 2005-726928P	P	20051014
	WO 2005-US42095	W	20051117

OTHER SOURCE(S): MARPAT 145:27984
GI

L6 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Tubulin binding compds. of formula I and hypoxia activated prodrugs of known tubulin binding compds. useful for treating cancer and other hyperproliferative diseases are disclosed. Compds. of formula I wherein A is (un)substituted indazoline, (un)substituted imidazopyridine, (un)substituted pyrazolopyridine, (un)substituted triazolopyrazine, (un)substituted azulene, etc.; X is O, NNH2 and derivs., and NOH and derivs.; Q3 - Q5, and Q8 are independently H, halo, amino, C1-6 (mono/di)alkylamino, OH, C1-6 alkoxy, NO2, CN, (hetero)aryl, etc.; and their tautomers, isomers, racemic, non-racemic mixts. of isomers, polymorphs, hydrates, or pharmaceutically acceptable salts and solvates there of is claimed. Example compound II was prepared by cross-coupling of 3-(3,4,5-trimethoxybenzoyl)-7-iodo-6-methoxyindazole with propargyl alc. All the invention compds. were evaluated for their tubulin binding anticancer activity. Compound II exhibited GI50 values of 630 nM after 2 h, and 10 nM after 3 days against H460 cell line. Compound II also showed GI50 values of 0.3 nM against MES-SA, 1.6 nM against, MES-SA/DX5, 1.9 nM against HT29, and 2.5 nM against T47D.

IT 889134-57-0P 889134-63-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (trimethoxybenzoyl)indazolines and related compds. as tubulin binding anti cancer agents and prodrugs thereof useful for treatment of cancers)

RN 889134-57-0 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-(3,4,5-trimethoxybenzoyl)- (CA INDEX NAME)

L6 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 889134-63-8 CAPLUS
CN 1H-Indazole-1-acetamide, 7-ethynyl-6-methoxy-3-(3,4,5-trimethoxybenzoyl)- (CA INDEX NAME)



L6 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:164871 CAPLUS
DOCUMENT NUMBER: 144:254122
TITLE: Preparation of indazole derivatives and ophthalmic compositions for treating ocular hypertension
INVENTOR(S): Doherty, James B.; Shen, Dong-Ming
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006020003	A2	20060223	WO 2005-US25136	20050715
WO 2006020003	A3	20060831		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005274972	A1	20060223	AU 2005-274972	20050715
CA 2574078	A1	20060223	CA 2005-2574078	20050715
EP 1771170	A2	20070411	EP 2005-771451	20050715
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1988903	A	20070627	CN 2005-80024510	20050715
JP 2008507521	T	20080313	JP 2007-522582	20050715
US 20080032951	A1	20080207	US 2006-630172	20061219
IN 2006CN04793	A	20071005	IN 2006-CN4793	20061229

PRIORITY APPLN. INFO.:			
	US 2004-589444P	P	20040720
	WO 2005-US25136	W	20050715

OTHER SOURCE(S): CASREACT 144:254122; MARPAT 144:254122
GI



I



II

AB Title compds. I [M, M1, M2 = CH or N; Z = N or C, when Z = N then the bond
between Y and Z is a single bond and between X and Y resp. represents CR1=N, CR1=CR1a, CR1a=CR1, or N=CR1, and when Z = C then X = O or S, Y represents CR1 and the bond between Y and Z is a double bond; R4 and R5 independently = H, OH, alkoxy, etc.; Q = unsatd. phosphonate derivative or
substituted carbonyl alkyl derivative; R1 = OH, alkoxy,, unsatd. phosphonate
derivative, etc.; R1a = H, (un)substituted alkyl, cycloalkyl, etc.], and their
pharmaceutically acceptable salts, are prepared and disclosed as potassium
channel blockers suitable for ophthalmic compns. fore treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. Thus, e.g., II was prepared by amidation
of (3-isobutyryl-6-methoxy-1H-indazol-1-yl)acetic acid (preparation given) with
di-n-butylamine. In assays for evaluating ability to block potassium channels, I was determined to possess IC50's in the range of about 1nM to about
20 μM. This invention also relates to the use of such compds. to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

IT 877144-05-3P 877144-10-0P 877144-11-1P
877144-12-2P 877144-13-3P 877144-14-4P
877144-15-5P 877144-16-6P 877144-17-7P
877144-18-8P 877144-21-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole derivs. and ophthalmic compns. thereof for treating
ocular hypertension)

RN 877144-05-3 CAPLUS
CN 1H-Indazole-1-acetamide, N-(3,3-dimethylbutyl)-N-ethyl-6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]- (CA INDEX NAME)



RN 877144-10-0 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]- (CA INDEX NAME)



RN 877144-11-1 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]-N,N-bis(2-methylpropyl)- (CA INDEX NAME)



RN 877144-12-2 CAPLUS
CN 1H-Indazole-1-acetamide, N-(cyclopropylmethyl)-6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]-N-propyl- (CA INDEX NAME)



RN 877144-13-3 CAPLUS
CN 1H-Indazole-1-acetamide, N-cyclohexyl-N-ethyl-6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]- (CA INDEX NAME)



RN 877144-14-4 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]-N,N-dipropyl- (CA INDEX NAME)



RN 877144-15-5 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]- (CA INDEX NAME)



RN 877144-16-6 CAPLUS
CN 1H-Indazole-1-acetamide, N-ethyl-6-methoxy-N-(3-methylbutyl)-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]- (CA INDEX NAME)



RN 877144-17-7 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]-N-propyl- (CA INDEX NAME)



RN 877144-18-8 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-N,N-bis(3-methylbutyl)-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]- (CA INDEX NAME)



RN 877144-21-3 CAPLUS
CN 1H-Indazole-1-acetamide, N-(3,3-dimethylbutyl)-6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]-N-propyl- (CA INDEX NAME)



IT 877144-28-0P 877144-29-1P 877144-30-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indazole derivs. and ophthalmic compns. thereof for treating
ocular hypertension)
RN 877144-28-0 CAPLUS
CN 1H-Indazole-1-acetamide, N-(3,3-dimethylbutyl)-N-ethyl-6-methoxy-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 877144-29-1 CAPLUS

CN 1H-Indazole-1-acetamide, 3-(2-bromo-2-methyl-1-oxopropyl)-N-(3,3-dimethylbutyl)-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 877144-30-4 CAPLUS
CN Phosphoric acid, 1-[1-[2-[(3,3-dimethylbutyl)ethylamino]-2-oxoethyl]-6-methoxy-1H-indazol-3-yl]-2-methyl-1-propen-1-yl dimethyl ester (CA INDEX NAME)



L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1241229 CAPLUS
DOCUMENT NUMBER: 144:6818
TITLE: Indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones as α7 nicotinic receptor agonists, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Xie, Wenge; Herbert, Brian; Schumacher, Richard A.; Ma, Jianguo; Nguyen, Truc Minh; Gauss, Carla Maria; Tehim, Ashok
PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005111038	A2	20051124	WO 2005-US15937	20050506
WO 2005111038	A3	20060831		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005243147	A1	20051124	AU 2005-243147	20050506
CA 2565984	A1	20051124	CA 2005-2565984	20050506
US 20050272735	A1	20051208	US 2005-123219	20050506
EP 1745046	A2	20070124	EP 2005-747486	20050506
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
BR 2005010212	A	20071016	BR 2005-10212	20050506
JP 2007538011	T	20071227	JP 2007-511654	20050506
MX 2006PA12880	A	20070126	MX 2006-PA12880	20061107
IN 2006DN06854	A	20070831	IN 2006-DN6854	20061117
NO 2006005622	A	20070202	NO 2006-5622	20061206
KR 2007015607	A	20070205	KR 2006-725685	20061206
CN 101124226	A	20080213	CN 2005-80023104	20070108

PRIORITY APPLN. INFO.: US 2004-568696P P 20040507
US 2004-574712P P 20040527
US 2004-626469P P 20041110
WO 2005-US15937 W 20050506
US 2005-568696P P 20050507

OTHER SOURCE(S): CASREACT 144:6818; MARPAT 144:6818
GI



I



II



III



IV



V

AB The invention relates to heteroaryl-substituted azabicyclic compds., e.g.,
I or II, which are ligands for nicotinic acetylcholine receptors (nAChR) and can be used for the activation of nAChRs and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. In compds. I and II, B is
CH2, C=O, or C=S; m is 1 or 2; Y is O or S; X1 to X4 are independently selected from N and (un)substituted C, wherein at most one of X1 to X4 is N; X5 and X6 are independently selected from CH, fluoro-substituted C1-6 alkoxy-C, and heterocyclyl-C, wherein no more than one of X5 and X6 is CH;
X7 is CH or N; and R is H, (halo)-C1-4 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, and C1-6 alkyl-C6-10 aryl. The invention also relates to
the preparation of the heteroaryl-substituted diazabicyclic compds., pharmaceutical compns. comprising those compds. and a pharmaceutically acceptable carrier, as well as to the use of the compns. as agonists for the α7 nAChR subtype. Acylation of 3-methoxythiophenol with oxalyl chloride followed by cyclization gave benzothiophenedione III, which underwent oxidative cleavage resulting in the formation of benzoisothiazolecarboxamide IV. Alkaline hydrolysis of IV to the carboxylic
acid was followed by coupling with 1,4-diazabicyclo[3.2.2]nonane to give compound V. The preferred compds. of the invention express binding affinities of 5 nM to 2.5 μM (no data).

L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 869783-57-3P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-N-(3-methoxybenzyl)-5-[[[(3-methoxybenzyl)amino]carbonyl]amino]-1H-indazole-1-carboxamide formate 869783-61-9P, 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-N-(4-fluorobenzyl)-5-[[[(4-fluorobenzyl)amino]carbonyl]amino]-1H-indazole-1-carboxamide formate 869783-65-3P, N-Cyclopentyl-5-[[(cyclopentylamino)carbonyl]amino]-3-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-1H-indazole-1-carboxamide formate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heteroaryl-substituted diazabicyclo[3.2.2]nonanes as α7 nicotinic receptor agonists)
RN 869783-57-3 CAPLUS
CN Formic acid, compd. with 3-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-N-[(3-methoxyphenyl)methyl]-5-[[[[(3-methoxyphenyl)methyl]amino]carbonyl]amino]-1H-indazole-1-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 869783-56-2
CMF C33 H37 N7 O5



CM 2

CRN 64-18-6
CMF C H2 O2

RN 869783-61-9 CAPLUS
CN Formic acid, compd. with 3-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-N-[(4-fluorophenyl)methyl]-5-[[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]-1H-

L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
indazole-1-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 869783-60-8
CMF C31 H31 F2 N7 O3



CM 2

CRN 64-18-6
CMF C H2 O2

RN 869783-65-3 CAPLUS
CN Formic acid, compd. with N-cyclopentyl-5-[[(cyclopentylamino)carbonyl]amino]-3-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-1H-indazole-1-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 869783-64-2
CMF C27 H37 N7 O3

L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 64-18-6
CMF C H2 O2

L6 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1075795 CAPLUS
DOCUMENT NUMBER: 143:347334
TITLE: Preparation of quinuclidine indazole, benzothiazole, benzisothiazole and benzisoxazoles as ligands for the α7 nicotinic acetylcholine receptor
INVENTOR(S): Xie, Wenge; Herbert, Brian; Schumacher, Richard; Nguyen, Truc Minh; Ma, Jianguo; Gauss, Carla Maria; Tehim, Ashok
PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 300 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092890	A2	20051006	WO 2005-US10120	20050325
WO 2005092890	A3	20060202		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005227324	A1	20051006	AU 2005-227324	20050325
CA 2560741	A1	20051006	CA 2005-2560741	20050325
US 20050234095	A1	20051020	US 2005-89533	20050325
EP 1735306	A2	20061227	EP 2005-745169	20050325
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 101001856	A	20070718	CN 2005-80016742	20050325
BR 2005008771	A	20070814	BR 2005-8771	20050325
JP 2007530590	T	20071101	JP 2007-505233	20050325
MX 2006PA10852	A	20070116	MX 2006-PA10852	20060922
NO 2006004826	A	20061220	NO 2006-4826	20061024
KR 2007015406	A	20070202	KR 2006-722085	20061024

PRIORITY APPLN. INFO.:			
		US 2004-555951P	P 20040325
		US 2004-616033P	P 20041006
		WO 2005-US10120	W 20050325

OTHER SOURCE(S): MARPAT 143:347334
GI



I II

AB Quinuclidine derivs. of formula I [Y = NR1C(X)A, C(X)NR1A, NR1CH2A, CH2NR1A; A = (substituted) indazole, benzothiazole, benzoisothiazole or benzisoxazole; X = O, S; R1 = H, alkyl, haloalkyl, cycloalkyl, cycloalkyl-alkyl] are prepared as ligands for nicotinic acetylcholine receptors (nACh receptors), especially the α7 nACh receptor subtype. The compds. can be used for the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Thus, II was prepared The binding affinities of the prepared compds. were between 2 nM and 25 μM.

IT 865885-89-8P 865885-90-1P 865885-92-3P
865885-94-5P 865886-26-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinuclidine indazole, benzothiazole, benzoisothiazole and benzisoxazole derivs. as ligands for α7 nACh receptor subunit)

RN 865885-89-8 CAPLUS
CN 1H-Indazole-1,3-dicarboxamide, N3-(3S)-1-azabicyclo[2.2.2]oct-3-yl-N1-[(3-methoxyphenyl)methyl]-5-[[[[(3-methoxyphenyl)methyl]amino]carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 865885-90-1 CAPLUS
CN 1H-Indazole-1,3-dicarboxamide, N3-(3S)-1-azabicyclo[2.2.2]oct-3-yl-N1-[(4-fluorophenyl)methyl]-5-[[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 865885-92-3 CAPLUS
CN Formic acid, compd. with N3-(3R)-1-azabicyclo[2.2.2]oct-3-yl-N1-cyclopentyl-5-[[(cyclopentylamino)carbonyl]amino]-1H-indazole-1,3-dicarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 865885-91-2
CMF C27 H37 N7 O3

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 865885-94-5 CAPLUS
CN Formic acid, compd. with N3-(3S)-1-azabicyclo[2.2.2]oct-3-yl-N1-propyl-5-[[(propylamino)carbonyl]amino]-1H-indazole-1,3-dicarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 865885-93-4
CMF C23 H33 N7 O3

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 865886-26-6 CAPLUS
CN Carbamic acid, [3-[[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]-1-[[(1-methylethyl)amino]carbonyl]-1H-indazol-5-yl]-, 1-methylethyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 865886-25-5
CMF C23 H32 N6 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:612302 CAPLUS
DOCUMENT NUMBER: 143:133366
TITLE: Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
INVENTOR(S): Xie, Wenge; Herbert, Brian; Ma, Jianguo; Nguyen, Truc Minh; Schumacher, Richard A.; Gauss, Carla-Maria; Tehim, Ashok
PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063767	A2	20050714	WO 2004-US42852	20041222
WO 2005063767	A3	20050825		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004309367	A1	20050714	AU 2004-309367	20041222
CA 2550689	A1	20050714	CA 2004-2550689	20041222
US 20050176754	A1	20050811	US 2004-18429	20041222
EP 1697378	A2	20060906	EP 2004-814981	20041222
EP 1697378	B1	20071121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1918167	A	20070221	CN 2004-80041966	20041222
BR 2004017323	A	20070327	BR 2004-17323	20041222
JP 2007515424	T	20070614	JP 2006-545564	20041222
ES 2295973	T3	20080416	ES 2004-814981	20041222
IN 2006DN03547	A	20070831	IN 2006-DN3547	20060620
MX 2006PA07168	A	20060907	MX 2006-PA7168	20060622
NO 2006003392	A	20060921	NO 2006-3392	20060721

PRIORITY APPLN. INFO.: US 2003-530891P P 20031222
US 2004-606897P P 20040903
WO 2004-US42852 W 20041222

OTHER SOURCE(S): MARPAT 143:133366
AB The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
invention relates to novel compds. for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, which act as ligands for the α7 nAChR subtype, methods of prepg. such compds., compns. contg. such compds., and methods of use thereof.
IT 858661-37-7P, 3-[(5-Methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]-N-propyl-5-[[(propylamino)carbonyl]amino]-1H-indazole-1-carboxamide hydroformate 858661-41-3P, N-(4-Fluorobenzyl)-5-[[[(4-fluorobenzyl)amino]carbonyl]amino]-3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]-1H-indazole-1-carboxamide hydroformate 858661-45-7P, N-Cyclopentyl-5-[[(cyclopentylamino)carbonyl]amino]-3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]-1H-indazole-1-carboxamide hydroformate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles preparation and use as α7 nicotinic receptor ligands for treating various nervous system diseases)
RN 858661-37-7 CAPLUS
CN Formic acid, compd. with 3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]-N-propyl-5-[[(propylamino)carbonyl]amino]-1H-indazole-1-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 858661-36-6
CMF C23 H33 N7 O3



CM 2

CRN 64-18-6
CMF C H2 O2

RN 858661-41-3 CAPLUS
CN Formic acid, compd. with N-[(4-fluorophenyl)methyl]-5-[[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]-3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]-1H-indazole-1-carboxamide (1:1) (CA

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
INDEX NAME)

CM 1

CRN 858661-40-2
CMF C31 H31 F2 N7 O3



CM 2

CRN 64-18-6
CMF C H2 O2

RN 858661-45-7 CAPLUS
CN Formic acid, compd. with N-cyclopentyl-5-[[(cyclopentylamino)carbonyl]amino]-3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]-1H-indazole-1-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 858661-44-6
CMF C27 H37 N7 O3

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 64-18-6
CMF C H2 O2

L6 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:259877 CAPLUS
DOCUMENT NUMBER: 142:336354
TITLE: Preparation of indazole derivatives as potassium channel blockers for treating ocular hypertension
INVENTOR(S): Chen, Meng Hsin; Doherty, James B.; Liu, Luping; Natarajan, Swaminathan; Tynebor, Robert M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005025568	A1	20050324	WO 2004-US28351	20040831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004271978	A1	20050324	AU 2004-271978	20040831
CA 2537430	A1	20050324	CA 2004-2537430	20040831
EP 1663221	A1	20060607	EP 2004-782774	20040831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1842335	A	20061004	CN 2004-80024337	20040831
JP 2007504236	T	20070301	JP 2006-525401	20040831
US 20070027188	A1	20070201	US 2006-570231	20060228
PRIORITY APPLN. INFO.:			US 2003-500090P P	20030904
			WO 2004-US28351 W	20040831

OTHER SOURCE(S): CASREACT 142:336354; MARPAT 142:336354
GI



Y-Y1-X1-X2-O-Z I



II

AB Indazoles I [R, R1 = H, (un)substituted OH, CO2H, NH2, SO3H, alkyl, CF3, NO2, CN, halogen; R2 = H, OH, (un)substituted alkyl, alkenyl, cycloalkyl, heterocyclyl, NH2, CO2H, aryl; R3 = H, (un)substituted alkyl, cycloalkyl, heterocyclyl, CO2H, aryl, NH2, CONH2, SO2H, SO2NH2, acyl, CF3, NO2, CN, halogen; QR2R3 = cyclic, heterocyclic; Q = N, O; X = bond, alkylene, oxoalkylene; X1 = bond, NH, O; X2 = bond, (un)substituted alkylene; Y = CO(CH2)n, CH2, (un)substituted CH(OH); n = 0-3; Y1 = (un)substituted aryl,
heterocyclyl; Z = (un)substituted (CH2)nOP(O)(OH)2] were prepared as potassium channel blockers for the treatment of glaucoma and other conditions which lead to elevated intraocular pressure. I have IC50 for inhibition of the maxi-K channel of 10-500 nM. Thus, the indazole II was prepared from 6-methoxy-1H-indazole-3-carboxaldehyde, 5-iodo-2-chloropyridine, BrCH2CONBu2, and HOCH2CH2OH, followed by phosphorylation.
IT 695206-75-8P 695206-77-0P 695206-89-4P
695206-91-8P 695207-89-7P 695209-09-7P
695209-11-1P 848420-11-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indazole derivs. as potassium channel blockers for treating
ocular hypertension)
RN 695206-75-8 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[[6-(2-hydroxyethoxy)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)

L6 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 695206-77-0 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(2-hydroxyethoxy)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695206-89-4 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[[6-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-91-8 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)

L6 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 695207-89-7 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(2-hydroxyethoxy)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695209-09-7 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[(6-chloro-3-pyridinyl)carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695209-11-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[(6-chloro-3-pyridinyl)carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 848420-11-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[(6-chloro-3-pyridinyl)carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



IT 695206-79-2P 695206-81-6P 695206-83-8P
695206-85-0P 695206-87-2P 695207-91-1P
695207-95-5P 695207-99-9P 695208-01-6P
695208-05-0P 695208-09-4P 848420-14-4P
848420-15-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of indazole derivs. as potassium channel blockers for treating ocular hypertension)

RN 695206-79-2 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-81-6 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-83-8 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695206-85-0 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-87-2 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695207-91-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-3-[[6-(2-hydroxyethoxy)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695207-95-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695207-99-9 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695208-01-6 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695208-05-0 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695208-09-4 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-3-[[6-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 848420-14-4 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-N,N-bis(3-methylbutyl)-3-[[6-[2-(phosphonooxy)ethyl]-3-pyridinyl]carbonyl]- (CA INDEX NAME)



RN 848420-15-5 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-6-methoxy-3-[[6-[2-(phosphonooxy)ethyl]-3-pyridinyl]carbonyl]- (CA INDEX NAME)



IT 848420-10-0P 848420-12-2P 848420-13-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole derivs. as potassium channel blockers for treating ocular hypertension)

RN 848420-10-0 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-6-methoxy-3-[[6-[2-(phosphonooxy)ethoxy]-3-pyridinyl]carbonyl]- (CA INDEX NAME)



RN 848420-12-2 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-[[6-[2-(phosphonooxy)ethoxy]-3-pyridinyl]carbonyl]-N,N-dipropyl- (CA INDEX NAME)



RN 848420-13-3 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-N,N-bis(3-methylbutyl)-3-[[6-[2-(phosphonooxy)ethoxy]-3-pyridinyl]carbonyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:1011963 CAPLUS
DOCUMENT NUMBER: 142:6526
TITLE: Preparation of indazolecarboxamides as factor VIIa and/or factor Xa inhibitors
INVENTOR(S): Nazare, Marc; Wehner, Volkmar; Laux, Volker; Urmann, Matthias; Bauer, Armin; Matter, Hans
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: Eur. Pat. Appl., 103 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1479675	A1	20041124	EP 2003-11303	20030519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004238499	A1	20041125	AU 2004-238499	20040505
CA 2528220	A1	20041125	CA 2004-2528220	20040505
WO 2004101556	A1	20041125	WO 2004-EP4753	20040505
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1628972	A1	20060301	EP 2004-731155	20040505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004010430	A	20060606	BR 2004-10430	20040505
JP 2006528942	T	20061228	JP 2006-529742	20040505
US 20040235824	A1	20041125	US 2004-849088	20040519
US 7365088	B2	20080429		
MX 2005PA12346	A	20060525	MX 2005-PA12346	20051116

PRIORITY APPLN. INFO.: EP 2003-11303 A 20030519
US 2003-507171P P 20030930
WO 2004-EP4753 W 20040505

OTHER SOURCE(S): CASREACT 142:6526; MARPAT 142:6526
GI



I



II

AB Title compds. [I, II; R = (substituted) mono- or bicyclic aryl, heterocyclyl; D = atoms to form a (substituted) 4-8 membered (heterocyclic) (aromatic) ring; R1 = H, (substituted) alkyl, aminocarbonylalkyl, alkoxycarbonylalkyl, aryl, heterocyclyl, etc.; R2 = bond, alkylene; V = (substituted) heterocyclyl, aryl; G = bond, (CH2)mNR10SO2(CH2)n, (CH2)mNR10SO2(CH2)n, (CH2)mCH(OH)(CH2)n, (CH2)m, (CH2)mO(CH2)n, (CH2)mS(CH2)n, etc.; m, n = 0-6; R10 = H, alkyl, hydroxyalkyl, alkoxyalkyl, perfluoroalkyl, with provisos], were prepared Thus, 1-[5-(5-chlorothien-2-yl)isoxazol-3-ylmethyl]-5-(cyanamide-1-carbonyl)-1H-indazole-3-carboxylic acid (1-isopropylpiperidin-4-yl)amide (preparation outlined) inhibited factor Xa with Ki = 5 nM.

IT 797804-17-2P 797804-20-7P 797804-22-9P
797804-24-1P 797804-26-3P 797804-32-1P
797804-33-2P 797804-37-6P 797804-38-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of indazolecarboxamides as factor VIIa and/or factor Xa inhibitors)

RN 797804-17-2 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[4-(1-piperidinylcarbonyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 797804-20-7 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[4-(4-morpholinylcarbonyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 797804-22-9 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 797804-24-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[4-(2-oxo-1-pyrrolidinyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 797804-26-3 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]- (CA INDEX NAME)



RN 797804-32-1 CAPLUS
CN 1H-Indazole-5-carboxylic acid, 1-[2-[(5-chloro-2-pyridinyl)amino]-2-oxoethyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)



RN 797804-33-2 CAPLUS
CN 1H-Indazole-5-carboxylic acid, 1-[2-[(5-chloro-2-pyridinyl)amino]-2-oxoethyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]- (CA INDEX
NAME)



RN 797804-37-6 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 797804-38-7 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]- (CA INDEX NAME)



IT 797804-41-2P 797804-45-6P 797804-48-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazolecarboxamides as factor VIIa and/or factor Xa inhibitors)

RN 797804-41-2 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

L6 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CRN 797804-38-7
CMF C23 H27 Cl N6 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 797804-45-6 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[4-(1-piperidinylcarbonyl)phenyl]amino]carbonyl]-, 2,2,2-trifluoroacetate (1:?)
(CA INDEX NAME)

CM 1

CRN 797804-17-2
CMF C27 H25 Cl N6 O3

L6 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 797804-48-9 CAPLUS
CN 1H-Indazole-5-carboxylic acid, 1-[2-[(5-chloro-2-pyridinyl)amino]-2-oxoethyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, hydrobromide (1:?) (CA INDEX NAME)

L6 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

●x HBr

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:430692 CAPLUS
DOCUMENT NUMBER:	141:7107
TITLE:	Preparation of 1H-indazoles as K channel blockers for use in ophthalmic compositions for treating ocular hypertension
INVENTOR(S):	Doherty, James B.; Chen, Meng-Hsin; Liu, Luping; Natarajan, Swaminathan R.; Shen, Dong-Ming; Tynebor, Robert M.
PATENT ASSIGNEE(S):	Merck & Co., Inc., USA
SOURCE:	PCT Int. Appl., 80 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043354	A2	20040527	WO 2003-US34959	20031104
WO 2004043354	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2505127	A1	20040527	CA 2003-2505127	20031104
AU 2003287481	A1	20040603	AU 2003-287481	20031104
EP 1581503	A2	20051005	EP 2003-781722	20031104
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006510742	T	20060330	JP 2005-507074	20031104
US 20060020000	A1	20060126	US 2005-530840	20050408

PRIORITY APPLN. INFO.:	US 2002-424790P	P	20021108
	US 2003-500094P	P	20030904
	WO 2003-US34959	W	20031104

OTHER SOURCE(S): MARPAT 141:7107
GI



I II

AB This invention relates to the preparation and use of title compds. I [wherein X = (CHR7)p, (CHR7)pCO; Y = CO(CH2)n, CH2, CH(OR); Q = N or O, wherein R2 is absent when Q = O; R = H or alkyl; R2 = H, OH, (CH2)nO(CH2)mOR, CO2R, NR2, or (un)substituted alkyl, alkenyl, alkoxy(alkyl), thioalkyl, cycloalkyl(alkyl), heterocyclyl(alkyl), aryl(alkyl); R3 = H, NO2, CN, halo, (CH2)nCO2R, (CH2)SO2R, (CH2)nSO2NR2, or (un)substituted alkyl, cycloalkyl(alkyl), heterocyclyl(alkyl), aryl(alkyl), alkoxy(alkyl), carbamoyl(alkyl), (CH2)nNH2; R4 and R5 = independently H, alkoxy, OH, alkyl, acyl, CO2R, SO3H, O(CH2)nNR2, OPO3H2, CF3, NR2, NO2, CN, halo, etc.; R6 = H, CO2R, COCO2R, or (un)substituted alkyl, aryl(alkyl), NH2, heterocyclyl(alkyl), aryloxy, cycloalkyl(alkyl), etc.; R7 = H, alkyl, (CH2)nCO2R, (CH2)nNR2; m = 0-3; n = 0-3; p = 0-3; and pharmaceutically acceptable salts, enantiomers, diastereomers, or mixts. thereof] and pharmaceutical compns. comprising them as potent K channel blockers for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient (no data). This invention also relates to the use of I to provide a neuroprotective effect to the eye of mammalian species, particularly humans (no data). For example, 3-benzoyl-6-methoxy-1H-indazole (preparation given) was N-alkylated with Me bromoacetate in the presence of NaH in DMF and the product hydrolyzed using LiOH in THF to afford II. Compds. of the invention inhibited maxi-K channels in TsA-201 cells with IC50 values < 20μM in a fluorescence assay and blocked the activity of maxi-K channels in human non-pigmented ciliary epithelial cells with IC50 values < 20μM in an electrophysiol. study.

IT 695209-09-7P 695209-11-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 1H-indazoles as K channel blockers for use in ophthalmic compns. for treating ocular hypertension)

RN 695209-09-7 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[(6-chloro-3-pyridinyl)carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695209-11-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[(6-chloro-3-pyridinyl)carbonyl]-6-methoxy-N,N-

bis(3-methylbutyl)- (CA INDEX NAME)



IT 695206-45-2P 695206-47-4P 695206-49-6P
695206-51-0P 695206-52-1P 695206-54-3P
695206-56-5P 695206-58-7P 695206-64-5P
695206-66-7P 695206-67-8P 695206-69-0P
695206-71-4P 695206-75-8P 695206-77-0P
695206-79-2P 695206-81-6P 695206-83-8P
695206-85-0P 695206-87-2P 695206-89-4P
695206-91-8P 695206-93-0P 695206-95-2P
695206-97-4P, N-(Cyclopropylmethyl)-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]-N-propylacetamide 695206-99-6P, N-(Cyclohexylmethyl)-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]-N-ethylacetamide 695207-01-3P, 2-[3-(2,2-Dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]-N-ethyl-N-(3-methylbutyl)acetamide 695207-09-1P, N-(3,3-Dimethylbutyl)-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]-N-ethylacetamide 695207-13-7P, N-Butyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]-N-propylacetamide 695207-15-9P, 2-[3-(2,2-Dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]-N-ethyl-N-(1,3-thiazol-2-yl)acetamide 695207-17-1P, 2-[3-(2,2-Dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]-N-(2,2-dimethylpropyl)-N-ethylacetamide 695207-19-3P
695207-21-7P 695207-23-9P 695207-25-1P
695207-27-3P 695207-29-5P 695207-31-9P
695207-33-1P 695207-35-3P 695207-37-5P
695207-39-7P 695207-41-1P 695207-43-3P
695207-45-5P 695207-47-7P 695207-49-9P
695207-51-3P 695207-53-5P 695207-60-4P
695207-62-6P 695207-64-8P 695207-69-3P
695207-73-9P 695207-75-1P 695207-77-3P
695207-79-5P 695207-81-9P 695207-85-3P
695207-89-7P 695207-91-1P 695207-95-5P
695207-99-9P 695208-01-6P 695208-05-0P
695208-09-4P 695208-11-8P 695208-13-0P
695208-15-2P 695208-17-4P 695208-19-6P
695208-22-1P 695208-24-3P 695208-26-5P
695208-28-7P 695208-34-5P 695208-36-7P
695208-38-9P 695208-42-5P 695208-49-2P
695208-52-7P 695208-55-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(maxi-K blocker; preparation of 1H-indazoles as K channel blockers for use in ophthalmic compns. for treating ocular hypertension)

RN 695206-45-2 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-ethyl-6-methoxy-N-2-thiazolyl- (CA INDEX NAME)



RN 695206-47-4 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-cyclohexyl-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695206-49-6 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-butyl-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695206-51-0 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-cyclopentyl-6-methoxy-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 695206-52-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695206-54-3 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N,N-diethyl-6-methoxy- (CA INDEX NAME)



RN 695206-56-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-6-methoxy-N-2-thiazolyl- (CA INDEX NAME)



RN 695206-58-7 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-6-methoxy-N-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 695206-64-5 CAPLUS
CN 1H-Indazole-1-acetamide, N-ethyl-6-methoxy-3-(2-methyl-1-oxopropyl)-N-2-thiazolyl- (CA INDEX NAME)



RN 695206-66-7 CAPLUS
CN 1H-Indazole-1-acetamide, N-cyclohexyl-N-ethyl-6-methoxy-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)





RN 695206-77-0 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(2-hydroxyethoxy)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695206-79-2 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-81-6 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)

RN 695206-67-8 CAPLUS
CN 1H-Indazole-1-acetamide, N-(2-ethyl-4-thiazolyl)-6-methoxy-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 695206-69-0 CAPLUS
CN 1H-Indazole-1-acetamide, N-cyclopentyl-6-methoxy-3-(2-methyl-1-oxopropyl)-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 695206-71-4 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-(2-methyl-1-oxopropyl)-N-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 695206-75-8 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[[6-(2-hydroxyethoxy)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-83-8 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695206-85-0 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-87-2 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695206-89-4 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[[6-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-91-8 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695206-93-0 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-(2,2-dimethyl-1-oxopropyl)-6-methoxy- (CA INDEX NAME)



RN 695206-95-2 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-N,N-bis(2-methylpropyl)- (CA INDEX NAME)



RN 695206-97-4 CAPLUS
CN 1H-Indazole-1-acetamide, N-(cyclopropylmethyl)-3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-N-propyl- (CA INDEX NAME)



RN 695206-99-6 CAPLUS
CN 1H-Indazole-1-acetamide, N-(cyclohexylmethyl)-3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695207-01-3 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy-N-(3-methylbutyl)- (CA INDEX NAME)



RN 695207-09-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-(3,3-dimethylbutyl)-3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695207-13-7 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-N-propyl- (CA INDEX NAME)



RN 695207-15-9 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy-N-2-thiazolyl- (CA INDEX NAME)



RN 695207-17-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-N-(2,2-dimethylpropyl)-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695207-19-3 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(cyclopentylcarbonyl)-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695207-21-7 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-(cyclopentylcarbonyl)-6-methoxy- (CA INDEX NAME)



RN 695207-23-9 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(cyclopentylcarbonyl)-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695207-25-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(cyclohexylcarbonyl)-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)





RN 695207-35-3 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[[6-(3-hydroxypropoxy)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695207-37-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(3-hydroxypropoxy)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695207-39-7 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-butyl-N-ethyl- (CA INDEX NAME)

RN 695207-27-3 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-(cyclohexylcarbonyl)-6-methoxy- (CA INDEX NAME)



RN 695207-29-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(cyclohexylcarbonyl)-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695207-31-9 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(3-hydroxypropoxy)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695207-33-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-3-[[6-(3-hydroxypropoxy)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695207-41-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-ethyl-N-5-thiazolyl- (CA INDEX NAME)



RN 695207-43-3 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N,N-dipropyl- (CA INDEX NAME)



RN 695207-45-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-2-thiazolyl- (CA INDEX NAME)



RN 695207-47-7 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-ethyl-N-2-thiazolyl- (CA INDEX NAME)



RN 695207-49-9 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-cyclohexyl-N-ethyl- (CA INDEX NAME)



RN 695207-51-3 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-ethyl-N-propyl- (CA INDEX NAME)



RN 695207-53-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-ethyl-6-methoxy-N-propyl- (CA INDEX NAME)



RN 695207-60-4 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-6-methoxy-N-methyl-N-2-thiazolyl- (CA INDEX NAME)



RN 695207-62-6 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-6-methoxy-N-methyl-N-[1-(2-thiazolyl)ethyl]- (CA INDEX NAME)



RN 695207-64-8 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-6-methoxy-N-methyl-N-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 695207-69-3 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-N-methyl-3-(2-methyl-1-oxopropyl)-N-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 695207-73-9 CAPLUS
CN 1H-Indazole-1-acetamide, N-ethyl-6-methoxy-3-(2-methyl-1-oxopropyl)-N-propyl- (CA INDEX NAME)



RN 695207-75-1 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-(2-methyl-1-oxopropyl)-N,N-dipropyl- (CA INDEX NAME)



RN 695207-77-3 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-6-methoxy-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 695207-79-5 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-(2-methyl-1-oxopropyl)-N-2-thiazolyl- (CA INDEX NAME)



RN 695207-81-9 CAPLUS
CN 1H-Indazole-1-acetamide, N-ethyl-N-(2-ethyl-4-thiazolyl)-6-methoxy-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 695207-85-3 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-(2-methyl-1-oxopropyl)-N-[1-(4-methyl-2-thiazolyl)ethyl]- (CA INDEX NAME)



RN 695207-89-7 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(2-hydroxyethoxy)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695207-91-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-3-[[6-(2-hydroxyethoxy)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695207-95-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695207-99-9 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695208-01-6 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695208-05-0 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695208-09-4 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-3-[[6-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695208-11-8 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy-N-(phenylmethyl)- (CA INDEX NAME)



RN 695208-13-0 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy-N-propyl- (CA INDEX NAME)



RN 695208-15-2 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy-N-(1-methylethyl)- (CA INDEX NAME)



RN 695208-17-4 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-N-methyl-N-(2-methylpropyl)- (CA INDEX NAME)



RN 695208-19-6 CAPLUS
CN 1H-Indazole-1-acetamide, N-(1,1-dimethylethyl)-3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695208-22-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 695208-24-3 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy-N-(1,3,4-thiadiazol-2-ylmethyl)- (CA INDEX NAME)



RN 695208-26-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy-N-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 695208-28-7 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-N-methyl- (CA INDEX NAME)



RN 695208-34-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695208-36-7 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695208-38-9 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695208-42-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-N-methyl-N-(3-methylbutyl)- (CA INDEX NAME)



RN 695208-49-2 CAPLUS
CN 1H-Indazole-1-acetamide, N-(3,3-dimethylbutyl)-3-(2,2-dimethyl-1-oxopropyl)-6-methoxy- (CA INDEX NAME)



RN 695208-52-7 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-N,N-diethyl-6-methoxy- (CA INDEX NAME)



RN 695208-55-0 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-N-methyl-N-propyl- (CA INDEX NAME)

L6 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L6 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:556140 CAPLUS
DOCUMENT NUMBER: 137:125159
TITLE: Preparation and antiviral activity of heterocyclic substituted 2-methylbenzimidazole antiviral agents
INVENTOR(S): Yu, Kuo-Long; Civiello, Rita L.; Combrink, Keith D.; Gulgeze, Hatice Belgin; Sin, Ny; Wang, Xiangdong; Meanwell, Nicholas; Venables, Brian Lee; Zhang, Yi; Pearce, Bradley C.; Yin, Zhiwei; Thuring, Jan Willem
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: U.S. Pat. Appl. Publ., 89 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020099208	A1	20020725	US 2001-994012	20011116
US 6774134	B2	20040810		
WO 2002062290	A2	20020815	WO 2001-US45149	20011120
WO 2002062290	A3	20021121		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002253794	A1	20020819	AU 2002-253794	20011120
EP 1343499	A2	20030917	EP 2001-270116	20011120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520387	T	20040708	JP 2002-562298	20011120
US 20040067997	A1	20040408	US 2003-643411	20030819
US 6844342	B2	20050118		

PRIORITY APPLN. INFO.:	US 2000-257139P	P	20001220
	US 2001-994012	A3	20011116
	WO 2001-US45149	W	20011120

OTHER SOURCE(S): MARPAT 137:125159
GI



I II

L6 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The title compds. [I; R1 = (CRaRb)nX; Ra, Rb = independently H, C1-6 (un)substituted alkyl; X = H, C1-6 (un)substituted alkyl; n = 1-6; R2, R5 = independently H or halogen; R3, R4 = independently H, halogen, C1-6 (un)substituted alkyl; Q = heterocyclic group], useful in the treatment of viral infections, more particularly, for the treatment of respiratory syncytial virus infection, were prepared E.g., a four-step synthesis of II, starting with 2-(chloromethyl)benzimidazole, was given. The antiviral activity of these compds. against respiratory syncytial virus (RSV) was determined in HEp-2 (ATCC CCL 23) cells. The title compds. I, disclosed herein, show antiviral activity with EC50s between 50 μM and 0.001 μM.
IT 443985-43-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and use of heterocyclic substituted 2-methyl-benzimidazole antiviral agents)
RN 443985-43-1 CAPLUS
CN 1H-Indazole-3-carboxylic acid, 1-[2-[[2-[[2-[(methylsulfonyl)amino]ethyl]amino]phenyl]amino]-2-oxoethyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:682077 CAPLUS
DOCUMENT NUMBER: 119:282077
TITLE: Silver halide photographic material
INVENTOR(S): Arai, Kazumi; Kato, Kazunobu
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05011384	A	19930122	JP 1991-191148	19910705
JP 2779712	B2	19980723		

PRIORITY APPLN. INFO.:	JP 1991-191148		19910705

AB The title material contains a compound represented by ED(Time)tYZ [ED = moiety releasing (Time)tYZ upon reaction with an oxidized developing agent; Time = divalent linking group; t = 0 or 1; Y = divalent group linked to ED(Time)t through a heteroatom; Z = Z1(X)NO2; Z1 = (substituted) aromatic or heterocyclic aromatic moiety which may consist of a single ring or fused rings; X = electron-attracting group]. The title material provides high contrast.
IT 151544-11-5
RL: USES (Uses)
(redox compound, in photog. material)
RN 151544-11-5 CAPLUS
CN 1H-Indazole-1-carboxylic acid, 3-[[[2-(methylsulfonyl)-4-nitrophenyl]amino]carbonyl]-, 2-[4-[(1H-benzotriazol-5-ylcarbonyl)amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:29827 CAPLUS
DOCUMENT NUMBER: 118:29827
ORIGINAL REFERENCE NO.: 118:5357a,5360a
TITLE: Silver halide photographic material
INVENTOR(S): Yagihara, Morio; Okamura, Hisashi; Kato, Kazunobu
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 43 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04136838	A	19920511	JP 1990-258925	19900928
PRIORITY APPLN. INFO.:			JP 1990-258925	19900928

AB In the title material comprising one or more silver halide emulsion layers, the said silver halide emulsion layers or one or more hydrophilic colloid layers contain a redox compound which releases a nucleating development inhibitor upon oxidation The title material gives high-quality images.
IT 145011-20-7
RL: TEM (Technical or engineered material use); USES (Uses)
(silver halide photog. materials containing)
RN 145011-20-7 CAPLUS
CN 1H-Indazole-1-carboxylic acid, 3-[[(4-nitrosophenyl)amino]carbonyl]-, 2-(4-butylphenyl)hydrazide (CA INDEX NAME)



L6 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:521408 CAPLUS
DOCUMENT NUMBER: 117:121408
ORIGINAL REFERENCE NO.: 117:20933a,20936a
TITLE: Silver halide photographic materials
INVENTOR(S): Nii, Kazumi; Okamura, Hisashi; Katoh, Kazunobu
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 75 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 479156	A1	19920408	EP 1991-116543	19910927
EP 479156	B1	19940112		
R: BE, DE, GB				
JP 04136840	A	19920511	JP 1990-258928	19900928
US 5252438	A	19931012	US 1991-763688	19910923
PRIORITY APPLN. INFO.:			JP 1990-258928 A	19900928

OTHER SOURCE(S): MARPAT 117:121408
AB A photog. material is described comprising ED-(Time)t-Y-L-Z or R1NA1NA2G1 (Time)t Y-L-Z [ED = releasing group; Time = divalent linking group; t = 0, 1; Y = divalent group containing heteroatom. bonded to (Time); L = group cleavable on coupling reaction; Z = monovalent functional group having development inhibiting effect; R1 = aliphatic, aromatic group; G1 = CO, COCO, CS, C(:NG2R2), P(:O)(G2R2)-, G2 = bond, O, S, NR2; R2 = R1, H; of A1 and A2, one of them is H, and the other one is H, acyl, alkylsulfonyl, arylsulfonyl]. The material is useful in formation of ultrahard neg. images by photomech. processes.
IT 143282-08-0
RL: USES (Uses)
(redox compound, for photog. emulsion)
RN 143282-08-0 CAPLUS
CN 1H-Indazole-1-carboxylic acid, 3-[[(4-nitrobenzoyl)oxy]methyl]-, 2-phenylhydrazide (CA INDEX NAME)



L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:458810 CAPLUS
DOCUMENT NUMBER: 117:58810
ORIGINAL REFERENCE NO.: 117:10225a,10228a
TITLE: Silver halide photographic material and image forming method using that material
INVENTOR(S): Katoh, Kazunobu; Okamura, Hisashi; Yagihara, Morio
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 63 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 480264	A1	19920415	EP 1991-116544	19910927
EP 480264	B1	20000209		
R: DE, FR, GB				
JP 04136843	A	19920511	JP 1990-258924	19900928
JP 2869577	B2	19990310		
US 5273859	A	19931228	US 1991-763702	19910923
CA 2052096	A1	19920329	CA 1991-2052096	19910924
PRIORITY APPLN. INFO.:			JP 1990-258924 A	19900928

AB Photog. halftone images of outstanding quality are obtained using a photog. film containing a first hydrazine derivative capable of releasing a development inhibitor as a result of oxidation with the developer (at least a portion of this inhibitor is released into a developer where it reacts with the developing agent and changes into a compound with little inhibiting effect), and (optionally) a second hydrazine derivative which has nucleating effect.
IT 142554-30-1
RL: USES (Uses)
(photog. film for halftone image production containing)
RN 142554-30-1 CAPLUS
CN 1H-Indazole-1,3-dicarboxylic acid, 5-nitro-, 3-(2-hydroxypropyl) ester, 1-[2-[4-[[2-[4-[(4-hydroxyphenyl)sulfonyl]phenoxy]-1-oxododecyl]amino]phenyl]hydrazide] (CA INDEX NAME)

L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    82.23     291.95

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -12.00     -12.00

STN INTERNATIONAL LOGOFF AT 06:38:32 ON 01 MAY 2008
```